Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review

被引:100
|
作者
Murage, Mwangi J. [1 ]
Tongbram, Vanita [2 ]
Feldman, Steven R. [3 ]
Malatestinic, William N. [1 ]
Larmore, Cynthia J. [1 ]
Muram, Talia M. [1 ]
Burge, Russel T. [1 ,4 ]
Bay, Charles [2 ]
Johnson, Nicole [2 ]
Clifford, Sarah [5 ]
Araujo, Andre B. [1 ]
机构
[1] Eli Lilly & Co, LCT South Bldg 145-2,Drop Code 5324, Indianapolis, IN 46221 USA
[2] ICON Plc, New York, NY USA
[3] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[4] Univ Cincinnati, Winkle Coll Pharm, Div Pharmaceut Sci, Cincinnati, OH USA
[5] ICON Plc, San Francisco, CA USA
来源
关键词
biologics; compliance; nonadherence; nonpersistence; factors; discontinuation; NECROSIS-FACTOR INHIBITORS; MODIFYING ANTIRHEUMATIC DRUGS; HEALTH-CARE COSTS; TREATMENT PATTERNS; BIOLOGIC THERAPIES; CONCOMITANT METHOTREXATE; US VETERANS; ETANERCEPT; ADALIMUMAB; DISEASE;
D O I
10.2147/PPA.S167508
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Proper adherence and persistence to medications are crucial for better quality of life and improved outcomes in rheumatoid arthritis (RA), psoriasis (PsO), and psoriatic arthritis (PsA). We systematically describe current adherence and persistence patterns for RA, PsO, and PsA, with a focus on biologics and identifying factors associated with adherence and persistence. Patients and methods: Using various databases, a systematic literature review of US-based studies published from 2000 to 2015 on medication adherence and persistence to biologics and associated factors was conducted among patients with RA, PsO, and PsA. Results: Using the medication possession ratio or the percentage of days covered >80%, RA and PsO adherence rates for etanercept, adalimumab, and infliximab ranged from 16% to 73%, 21% to 70%, and 38% to 81%, respectively. Using the criteria of a >= 45-day gap, RA persistence rates for etanercept, adalimumab, and infliximab ranged from 46% to 89%, 42% to 94%, and 41% to 76%, respectively. In PsO, persistence rates for etanercept and adalimumab ranged from 34% to 50% and 50% to 62%, respectively. Similar persistence rates were observed in PsA. Experienced biologics users showed better adherence and persistence. Younger age, female gender, higher out-of-pocket costs, greater disease severity, and more comorbidities were associated with lower adherence and persistence rates. Qualitative surveys revealed that nonpersistence was partly due to perceived ineffectiveness and safety/tolerability concerns. Conclusion: Biologic adherence and persistence rates in RA, PsO, and PsA in the United States were low, with significant opportunity for improvement. Various factors - including decrease in disease severity; reduction of comorbidities; lower out-of-pocket costs; refilling at specialty pharmacies; and awareness of drug effectiveness, safety, and tolerability - can inform targeted approaches to improve these rates.
引用
收藏
页码:1483 / 1503
页数:21
相关论文
共 50 条
  • [41] Medication adherence in rheumatoid arthritis patients: Older is wiser
    Park, DC
    Hertzog, C
    Leventhal, H
    Morrell, RW
    Leventhal, E
    Birchmore, D
    Martin, M
    Bennett, J
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1999, 47 (02) : 172 - 183
  • [42] PREDICTORS OF MEDICATION ADHERENCE IN SERBIAN PATIENTS WITH RHEUMATOID ARTHRITIS
    Zivolinovic, S.
    Nedovic, J.
    Jankovic, T.
    Damjanov, N.
    Damjanov, Nemanja
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1330 - 1330
  • [43] Identifying Predictors of Medication Adherence In Patients with Rheumatoid Arthritis
    Salt, Elizabeth G.
    Frazier, Susan K.
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S341 - S342
  • [44] MEDICATION ADHERENCE AMONG ALBANIAN PATIENTS WITH RHEUMATOID ARTHRITIS
    Kellici, S.
    Mihani, J.
    Miraci, M.
    Fida, M.
    Backa, T.
    [J]. JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (01): : 125 - 131
  • [45] Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review
    Puig, Lluis
    Rodriguez Fernandez-Freire, Lourdes
    Burgos-Pol, Ramon
    Gomez, Ismael
    Peral, Carmen
    Gomez, Susana
    Rebollo Laserna, Francisco Jose
    [J]. DERMATOLOGY AND THERAPY, 2019, 9 (03) : 479 - 496
  • [46] Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review
    Lluís Puig
    Lourdes Rodríguez Fernández-Freire
    Ramón Burgos-Pol
    Ismael Gomez
    Carmen Peral
    Susana Gomez
    Francisco José Rebollo Laserna
    [J]. Dermatology and Therapy, 2019, 9 : 479 - 496
  • [47] Nailfold capillaroscopy as diagnostic test in patients with psoriasis and psoriatic arthritis: A systematic review
    Lazar, L. T.
    Guldberg-Moller, J.
    Lazar, B. T.
    Mogensen, M.
    [J]. MICROVASCULAR RESEARCH, 2023, 147
  • [48] NAILFOLD CAPILLAROSCOPY AS DIAGNOSTIC TEST IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS: A SYSTEMATIC REVIEW
    Lazar, Luna Toppenberg
    Guldberg-Moller, Jorgen
    Lazar, Benjamin Toppenberg
    Mogensen, Mette
    [J]. ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 45 - 45
  • [49] ECONOMIC EVALUATIONS OF ETANERCEPT IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS IN SPAIN: A SYSTEMATIC REVIEW
    Peral, C.
    Gomez, I
    Burgos, R.
    Rebollo, F.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A530 - A530
  • [50] Patient adherence to TNFα inhibitors in rheumatoid arthritis and psoriatic arthritis
    Oskarsdottir, Thorunn
    Gunnarsdottir, Anna Ingibjorg
    Gudbjornsson, Bjorn
    Gunnarsson, Petur Sigurdur
    Love, Thorvardur
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (01) : 182 - 182